<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508454</url>
  </required_header>
  <id_info>
    <org_study_id>14-042</org_study_id>
    <nct_id>NCT02508454</nct_id>
  </id_info>
  <brief_title>The Miami Heart Study at Baptist Health South Florida</brief_title>
  <acronym>MiHEART</acronym>
  <official_title>The Miami Heart Study at Baptist Health South Florida: A Prospective Study of Sub-Clinical Cardiovascular Disease and Emerging Cardiovascular Risk Factors in Asymptomatic Young &amp; Middle-Aged Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baptist Health South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quest Diagnostics-Nichols Insitute</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baptist Health South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Miami Heart Study at Baptist Health will be an observational, longitudinal and&#xD;
      prospective cohort study in a target population of 4000 healthy subjects (40-65 years old)&#xD;
      consisting of members from the Greater Miami Area (including eligible BHSF(Baptist Health&#xD;
      South Florida) employees). Baseline examination will consist of (1) assessment for&#xD;
      cardiovascular risk factors (including lifestyle and psychosocial factors); (2) screening for&#xD;
      subclinical atherosclerosis using Coronary CT angiogram, Coronary Artery Calcium (CAC)&#xD;
      testing, vascular 2D/3D ultrasound, endothelial function, arterial stiffness and (3) blood&#xD;
      sampling for determination of traditional risk factors, advanced &quot;omics&quot; and biobanking.&#xD;
      Participants will be followed yearly via telephone, email, or mail for change in health&#xD;
      status with a focus on cardiovascular disease events, including acute myocardial infarction&#xD;
      and other forms of coronary heart disease (CHD), stroke, and congestive heart failure;&#xD;
      mortality; and for cardiovascular disease interventions.&#xD;
&#xD;
      The Miami Heart Study at Baptist Health is expected to identify new imaging and biological&#xD;
      factors associated with the presence and feature of earliest markers of subclinical&#xD;
      atherosclerotic disease and provide opportunities for discovery/validation of novel&#xD;
      biomarkers to identify these high-risk features. This is expected to lead to advances in&#xD;
      understanding of evolution and progression of atherosclerotic cardiovascular disease starts&#xD;
      with an ultimate goal of establishing more personalized, evidence-based approach to medical&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      What is this study about? The Miami Heart Study is a long term observational research study&#xD;
      which is designed to identify new and novel relationships between risk factors, genetics,&#xD;
      lifestyle behaviors and cardiovascular disease in the greater Miami area. Miami is uniquely&#xD;
      situated to capture a diverse, multi-ethnic population. As an employee of Baptist Health and&#xD;
      a very important stakeholder in Baptist Health's mission, you are being asked to take part in&#xD;
      this research study. The investigators expect approximately 4,000 members of the South&#xD;
      Florida community and/or employees of Baptist Health to participate in this study over the&#xD;
      next 5 years.&#xD;
&#xD;
      The research study aims to better understand heart disease and what causes it. Heart disease&#xD;
      often starts many years before a person has a heart attack or develops symptoms of heart&#xD;
      disease. This is called subclinical disease - and it refers to heart disease and the body&#xD;
      processes causing heart disease, at a stage before any symptoms are experienced. Although&#xD;
      doctors and researchers have a good understanding of heart disease in some areas, subclinical&#xD;
      disease is not very well understood.&#xD;
&#xD;
      Better understanding subclinical disease can allow doctors and healthcare staff to intervene&#xD;
      and prevent the process from developing further and causing symptomatic (with symptoms) heart&#xD;
      disease. Progression refers to the process by which subclinical (without symptoms) heart&#xD;
      disease develops into clinical (with symptoms) disease.&#xD;
&#xD;
      Therefore, the purpose of this research study is to:&#xD;
&#xD;
        -  To examine the presence and severity of subclinical disease in the South Florida&#xD;
           community.&#xD;
&#xD;
        -  To examine what unique factors contribute to development of subclinical disease and&#xD;
           appearance of clinical symptoms.&#xD;
&#xD;
      In the future, the investigators hope this information will allow us to better predict and&#xD;
      prevent the development heart disease in diverse populations. Participants will be asked to&#xD;
      come to the Miami Heart Study clinic for an examination that may take 4 to 6 hours to&#xD;
      complete. During the examination, information about the participant's health will be&#xD;
      collected and standard procedures routinely done a physician's office such as height, weight,&#xD;
      and blood pressure will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in presence of subclinical cardiovascular disease burden among cohort as measured through yearly followup questionnaire.</measure>
    <time_frame>Participants will be followed yearly for 5 years following completion of thier baseline visit.</time_frame>
    <description>To assess and characterize the presence of subclinical cardiovascular disease burden among middle-aged asymptomatic individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in severity of subclinical cardiovascular disease burden among cohort as measured through yearly followup questionnaire.</measure>
    <time_frame>Participants will be followed yearly for 5 years following completion of thier baseline visit.</time_frame>
    <description>To assess and characterize the severity of subclinical cardiovascular disease burden among middle-aged asymptomatic individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associated cost savings of early discovery of disease.</measure>
    <time_frame>Participants will be followed yearly for 5 years following completion of thier baseline visit.</time_frame>
    <description>To develop population-based methods for characterizing cardiovascular risk among middle-aged asymptomatic persons as well cost effectiveness for such paradigms in appropriately resource allocation for early cardiovascular disease management.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Greater Miami Area Community</arm_group_label>
    <description>Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baptist Health South Florida Employees</arm_group_label>
    <description>Employees of BHSF who qualify for the study and enroll.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Approximately 115 mls of blood will be drawn by a Registered Nurse. Blood samples will be&#xD;
      tested for markers of the diseases and health conditions under investigation. These will&#xD;
      include standard markers (cholesterol, blood sugar, etc) and novel markers which are not&#xD;
      commonly evaluated by a physician. Additionally, any remaining blood samples will be stored&#xD;
      and kept for future risk factor evaluation, biomarker testing and genetic studies.&#xD;
&#xD;
      Whole blood and serum will be retained.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Since the MiHEART Study is primarily concerned with the determinants and natural history of&#xD;
        subclinical cardiovascular disease, participants with known clinical disease will not be&#xD;
        recruited. Most exclusion criteria relate to the long-term nature of the study or to&#xD;
        incompatibility with certain study procedures. Eligibility (or ineligibility) status will&#xD;
        be determined from self-reported information.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current full time/part-time employees of BHSF (occupational cohort) or resident of&#xD;
             Greater Miami Area for at least six months (community cohort)&#xD;
&#xD;
          -  Age 40 to 65 years&#xD;
&#xD;
          -  Asymptomatic individuals free of any known cardiovascular event&#xD;
&#xD;
          -  Able to comprehend and sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of major cardiovascular events (angina, myocardial infarction, prior&#xD;
             coronary revascularization)&#xD;
&#xD;
          -  History of cerebrovascular disease including stroke and transient ischemic attack&#xD;
             (TIA)&#xD;
&#xD;
          -  History of peripheral arterial disease (PAD)&#xD;
&#xD;
          -  History of either diagnosis or surgery for Abdominal Aortic Aneurysm (AAA)&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Weight greater than 350 lbs&#xD;
&#xD;
          -  Any contraindication to CT scans or iodinated contrast&#xD;
&#xD;
          -  Active treatment for cancer&#xD;
&#xD;
          -  Currently pregnant, breastfeeding, or suspect they may be pregnant.&#xD;
&#xD;
          -  Patients who do not agree to an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khurram Nasir, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baptist Health South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Health South Florida Corporate Office</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://miamiheartstudy.com/en/Pages/default.aspx</url>
    <description>Miami Heart Study Website - English</description>
  </link>
  <link>
    <url>http://miamiheartstudy.com/sp/Paginas/inicio.aspx</url>
    <description>Miami Heart Study Website -Espa√±ol</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Screening</keyword>
  <keyword>Biobanking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

